KRYS
$256.33
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States.
Recent News
Is It Too Late To Consider Krystal Biotech (KRYS) After Strong Multi‑Year Share Gains?
Wondering whether Krystal Biotech at around US$256 per share still offers value, or if most of the upside has already played out? This article breaks down what the current price might be implying. The stock has had a mixed run, with a 1.8% decline over the last week and a 7.3% decline over the last month, but it is still up 3.8% year to date and 36.0% over the last year, with a very large return over the last 3 years and a 251.9% gain over 5 years. Recent attention on Krystal Biotech has...
Updated YJUVEK Label and KB803 Progress Could Be A Game Changer For Krystal Biotech (KRYS)
In September 2025, the FDA approved an updated label for Krystal Biotech’s beremagene geperpavec-svdt (B-VEC/YJUVEK), reflecting evolving treatment guidance for epidermolysis bullosa and reinforcing its role in this rare disease space. This label update, alongside progress on Krystal’s pipeline candidate KB803, underscores how regulatory evolution and innovation may reshape the epidermolysis bullosa treatment landscape. We’ll now examine how the updated FDA label for B-VEC/YJUVEK may...
What to Know About This Obesity Drug Developer That Just Drew a New $7 Million Investment
Viking Therapeutics develops clinical-stage therapies for metabolic and endocrine disorders, aiming to address unmet medical needs.
This Biotech With a Breakout MS Drug Draws $8 Million Investment Amid 30% Stock Drop
This biopharma firm develops therapies for B-cell malignancies and autoimmune diseases, with a focus on oncology and immunology.
Guggenheim Lifts PT on Krystal Biotech (KRYS) to $284 From $224
Krystal Biotech, Inc. (NASDAQ:KRYS) is one of the top gene therapy stocks to buy according to hedge funds. On February 25, Guggenheim revised the price target on Krystal Biotech, Inc. (NASDAQ:KRYS) to $284 from $224 and reiterated a Buy rating on the shares following the company’s fiscal Q4 report. Krystal Biotech, Inc. (NASDAQ:KRYS) announced its […]